The China Securities Regulatory Commission has approved the IPO registration of Lieqi Intelligent on the Growth Enterprise Market.
On August 21, the China Securities Regulatory Commission issued the "Approval on the Registration of the Initial Public Offering of Shares by Suzhou Lieqi Intelligent Equipment Co., Ltd."
On August 21, the China Securities Regulatory Commission issued the "Approval for Suzhou LIEQI Intelligent Equipment Co., Ltd. to Register Its First Public Offering of Stocks." It is reported that LIEQI Intelligent intends to list on the Growth Enterprise Market of the Shenzhen Stock Exchange, with Guotai Junan Securities as its sponsor, aiming to raise 913.41 million yuan.
The prospectus shows that LIEQI Intelligent is a leading high-end intelligent equipment manufacturer in China, focusing on the research, development, production, and sales of intelligent production equipment in the fields of optical communication, semiconductors, and automotive automation. After years of technological accumulation and market development, the company's products have covered the core processes of optical module packaging and testing, including key procedures such as die bonding, coupling, and aging tests. The related equipment is essential for ensuring the transmission efficiency and reliability of optical modules, which are ultimately applied in the data communication and telecommunications markets. Meanwhile, relying on the technological advantages of automation equipment accumulated in the field of optical communication, the company is actively expanding into the semiconductor and automotive automation intelligent equipment sectors, continuously strengthening its overall competitive strength.
Related Articles

General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint

RECOMMEND





